Amphista Therapeutics

The company develops targeted protein degradation (TPD) therapeutics using proprietary Targeted Glue technology to selectively trigger the destruction of pathogenic proteins. These rationally designed molecules are engineered to address performance limitations of traditional PROTAC and glue technologies, enabling a wider range of tissue and indication targets. The firm focuses on creating medicines for various disease indications within the biopharmaceutical sector.